Scientific Coordinating Committee (SCC)

The Scientific Coordinating Committee is in charge of coordinating the activities of the Network Scientific Committee (NSC) and developing new strategies, projects and studies.

It includes 5 five members appointed by the NSC and two deputies:

Former Member of the Italian and European Parliament, she is President of the Gianni Benzi Pharmacological Research Foundation, a registered “not-for-profit” scientific research organisation. She has been the Coordinator of the Network of Excellence TEDDY/Task-force in Europe for Drug Development in the Young and currently she is scientific Coordinator of DEEP, an FP7 funded project aimed to increase availability of paediatric medicines of high therapeutic interest. DEEP includes many Countries in the Mediterranean area, such as Albania, Cyprus, Egypt, Greece, Italy, Tunisia. She is also member of the Executive Board of the FP7 GRiP (Global Research in Paediatrics) Network of Excellence and partner of several EC approved projects (FP7/DG-SANCO Health Programs): InNerMeD-I-Network, GAPP – GAbapentin in Paediatric Pain, CloSed – Clonidine for Sedation of paediatric patients in intensive care units. From 2008 to 2014 Adriana Ceci has been member of the European Medicines Agency’s Paediatric Committee (PDCO).

Pediatric intensivist and Associate Professor in Pediatric Clinical Pharmacology at Erasmus MC Sophia Children’s Hospital and serves as the Director of PharmaKids, the Erasmus Expertise Center for Pediatric Therapeutics and the Medicines for Children Research Center-the Netherlands. She received her PhD from Erasmus University and trained as a clinical pharmacologist at the Hospital for Sick Children in Toronto. Current Dutch Research Council and European Union supported research focuses on developmental pharmacology, more specifically on drug metabolism, drug transport and with a special interest in sedative and analgesic drugs. Dr de Wildt published over 65 international peer-reviewed papers in the field of pediatric pharmacology/intensive care. As a primary investigator, Dr. de Wildt holds currently 3 million euros in research grants, of which >2 million euros from the Dutch Research Council, ZonMW and the EU.

Neonatal Consultant at Liverpool Women’s NHS Foundation Trust and Senior Lecturer in Neonatology at the University of Liverpool. He trained in Medicine at the University of St Andrews, Scotland and Manchester University, specialising in Paediatrics and Neonatology in the North West of England and his PhD is in placental physiology. The professional achievements Mark is most proud of is delivering early phase studies in premature neonates (First-in-human; Phase 0 etc.) and his hopes are to improve the access to children and babies of high quality medicines through rational drug development based on assessment of how medicines are used through work on specific medicines for babies and by support generalisation of this work through research networks. Mark believes that the most important and realistic goals that he and his colleagues’ current focus worldwide should include insight on what children need as well as meeting academic drivers and to do the work needed to bridge between curiosity-driven research and clinical application. The most significant professional influence on Mark came from his first Science teacher who showed him the value of clarity of thought when describing research. In his spare time Mark’s interests lie in European History and Classical Music (except most of the 19th Century).

Head of the Paediatric Clinical Study Centre at the Department of Paediatric and Adolescent Medicine and member of the European Medicines Agency’s Paediatric Committee (PDCO). She has more than 10 years’ experience in paediatric medicine research. She spent five years at the Centre for Paediatric Pharmacy Research, the School of Pharmacy, University of London, where she was UK-coordinator of TEDDY. Currently, she is a member of the Scientific and Editorial Board of ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects). She also worked as a Clinical Research Scientist for THERAKIND being involved in the preparation of clinical documents related to regulatory aspects of paediatric medicines and currently acts as consultant for such occasions.

Professor and Chairman of Dept. Paediatrics at the Children’s Hospital Bambino Gesù, Director of the School of Specialty in Paediatrics; Director of the PhD program in Immunology Molecular Medicine and Applied Biotechnologies; Director of the Masters Program in Paediatric Sciences at the Children’s Hospital Bambino Gesù/ University of Rome Tor Vergata, (Italy). He is Delegate Paediatric Committee (PDCO) and Delegate to ENPREMA (European Network for Pediatric Research) at the European Medicines Agency. From 1987 to 2000 he was associate Professor of the Chair of Paediatrics. He created a group of pediatricians specialising in Clinical Immunology and at the same time, he organised the Diagnostic Laboratory for performing immunoassays. He was visiting Professor at the Department of Immunology, MTC, Karolinska Institute, Stockholm (1988-1996).

Lawyer and Professor (P.A.S.T) at Aix-Marseille University (Espace Ethique Méditerranéen) specialised in Health Law and Biomedical Ethics. Former member of Paediatric Committee at the European Medicine Agency (2008-2011), she has been member of the (EMA) Working Group for Third Countries Clinical Trials. Author of a book and more than 40 publications in national and international journals. Speaker invited in more than 50 conferences in 15 countries, she has also lectured in several training courses in European universities. Member of the Board of the international consortium TEDDY (Task-force in Europe for Drug Development for the Young), she is also expert/legal adviser of many EU-funded projects. Member of international and European scientific societies (WAML, EAHL, IIREB, UNESCO Geobs)

Professor of Paediatric Medicines Research, Director of Centre for Paediatric Pharmacy Research Areas of Expertise Health Service Research, Paediatric Drug Safety, Pharmacovigilance, Medication Error, Pharmacoepidemiology, Public Health, Medicines Management, Paediatric Pharmacy. He qualified as a pharmacist in 1992 and worked at the former Medicines Control Agency in the Yellow Card system between 1992 and 1993, then he started his research career in medication safety. He took up a research pharmacist post at the David Lewis Centre for Epilepsy to investigate the safety of new antiepileptic drugs between 1994 and 1997. He was awarded his PhD from Manchester Medical School in 1998 for his work at the David Lewis Centre. In 1997, he took up a lecturer in pharmacy practice post at the University of Bradford and was promoted to Senior Lecturer in 2001. In 2002, he moved to The School of Pharmacy, University of London to set up the Centre for Paediatric Pharmacy Research. He was awarded a Department of Health Public Health Career Scientist Award in 2002; he is the only pharmacist to date to have received such an Award. Professor Wong also received the Chemist and Druggist’s Pharmacy Practice Research Medal 2004 for his research in paediatric medicines. He has received research grants from the UK Medical Research Council, Engineering and UK Physical Science Research Council, UK Economic and Science Research Council, Department of Health in England, European Commissioners and the pharmaceutical industry. He has been an advisor to the Department of Health, World Health Organisation, European Medicines Agency and the pharmaceutical industry.